Management

Bram Bout CEO and Chairman of the Management Board Dr. Abraham (Bram) Bout is Chief Executive Officer of Bioceros BV. Prior to joining Bioceros he was employed by Crucell (from 1993 till March 2007), where he held several management positions with increasing responsibility. His last position at Crucell was Vice President, Protein Production. Dr. Bout is co-inventor of the human PER.C6^® production platform which is used for the development and manufacturing of vaccines, monoclonal antibodies, therapeutic proteins and gene therapy products. He studied Chemistry at the University of Amsterdam and his PhD thesis was on peroxisomal storage disorders. Dr. Bout is also Chief Technology Officer at ProFibrix BV (Leiden, The Netherlands) and is member of the Scientific Advisory Boards of Proteonic BV (Leiden, The Netherlands) and CELLution BV (Assen, The Netherlands). He published over 50 scientific articles and is co-inventor on 90 patents about the PER.C6^® cell line technology and in the field of recombinant protein production and gene therapy.

Remco M. Brandt Chief Operating Officer & Managing director Mr. Brandt holds a Master of Science degree in Management and held several scientific and management positions over the last decades in both Academic institutions and biotech companies in the Europe and the US. He was closely involved in the set up of several new life science laboratories & companies. He has a broad experience in regulations, permits, HR and facility management specifically for biotech-oriented organizations. Most recently he was CEO of Cilian AG, a small German biopharmaceutical company. He is founder of Life Science Purchasing Power BV, a purchase service provider solely for Biotech companies. Mr. Brandt is author/co-author of over 30 papers in international scientific journals in the field of immunology. Over the years he has raised over €10 million in venture capital.

Louis Boon Chief Scientific Officer Dr. Louis Boon received his Ph.D. in Biochemistry at the University of Amsterdam. He also carried out post-doctoral positions at the University of Amsterdam. Thereafter he was one of the founders of PanGenetics and since the merger between PanGenetics and Tanox Inc. Houston (USA), he held the position of VP preclinical, in which he was worldwide responsible for pre-clinical safety assessments and animals studies for the Tanox group. In 2003 he was one of the founders of Bioceros BV where he currently holds a position of Chief Scientific Officer (CSO). In addition, he held a position as CSO for 4AZA Bioscience NV and VP Preclinical (ad interim) for PanGenetics BV until the end of 2006. He has extensive experience in molecular and cellular immunology and in therapeutic antibody development and has been involved in the trajectory of preclinical preparation and design of First into Man studies using therapeutic antibodies. Dr. Boon is author/co-author of over 120 papers in international scientific journals in the field of medical biotechnology.